The impact of human papillomavirus vaccination on cervical cancer prevention efforts

Gynecologic Oncology

Volumn 114, Issue 2, 2009, Pages 360-364

  Massad, L Stewart ^a   Einstein, Mark ^b   Myers, Evan ^c   Wheeler, Cosette M ^d,e   Wentzensen, Nicolas ^f   Solomon, Diane ^g  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^e UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^f Division of Cancer Epidemiology and Genetics   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cervical cancer prevention; HPV epidemiology; HPV vaccine; Human papillomavirus (HPV); Test accuracy

Indexed keywords

WART VIRUS VACCINE;

CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CYTOLOGY; DRUG EFFICACY; DRUG UTILIZATION; EMERGENCY HEALTH SERVICE; FALSE POSITIVE RESULT; FEMALE; HEALTH PROGRAM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFECTION CONTROL; PAPANICOLAOU TEST; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SCREENING TEST; SEXUAL INTERCOURSE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; WART VIRUS;

FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 67549124660     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.04.005     Document Type: Review

References (42)

1. The Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369 (2007) 1861-1868
2. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomized controlled trial. Lancet 369 (2007) 2161-2170
3. Jemal A., Siegel R., Ward E., Hao Y., Xu J., et al. Cancer statistics, 2008. CA Cancer J. Clin. 58 (2008) 71-96
4. Saslow D., Runowicz C.D., Solomon D., Moscicki A.B., SMight R.A., Eyre J.H., and Cohen C. American Cancer Society Guideline for the early detection of cervical neoplasia and cancer. CA Cancer J. Clin. 52 (2002) 342-362
5. American College of Obstetricians and Gynecologists. Routine cancer screening. ACOG Committee Opinion No. 356. Obstet. Gynecol. 108 (2006) 1611-1613
6. Wright T.C., Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., and Solomon D for the 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. J. Lower Genit. Tract. Dis. 11 (2007) 201-222
7. Saslow D., Castle P.E., Cox J.T., Davey D.D., Einstein M.H., Ferris D.G., et al. American Cancer Society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J. Clin. 57 (2007) 7-28
8. Sirovich B.E., and Welch H.G. The frequency of Pap smear screening in the United States. J. Gen. Intern. Med. 19 (2004) 243-250
9. Sawaya G.F., McConnell J., Kulasingam S.L., Lawson H.W., Kerlikowske K., et al. Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N. Engl. J. Med. 349 (2003) 1501-1509
10. Quinn M., Babb P., Jone J., and Allen E. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 318 (1999) 904-908
11. Stokes-Lampard H., Wilson S., Waddell C., Ryan A., Holder R., and Kehoe S. Vaginal vault smears after hysterectomy for reasons other than malignancy: a systematic review of the literature. BJOG 113 (2006) 1354-1365
12. Meissner H.I., Tiro J.A., Haggstrom D., Lu-Yao G., and Breen N. Does patient health and hysterectomy status influence cervical cancer screening in older women?. J. Gen. Intern. Med. 23 (2008) 1822-1828
13. Ferenczy A., Choukroun D., and Arseneau J. Loop electrosurgical excision procedure for squamous intraepithelial lesions of the cervix: advantages and potential pitfalls. Obstet. Gynecol. 87 (1996) 332-337
14. Arbyn M., Kyrgiou M., Simoens C., Ralfu A.O., Koliopoulos G., Martin-Hirsch P., et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 337 (2008) a1284
15. Spence A.R., Goggin P., and Franco E.L. Process of care failures in invasive cervical cancer: systematic review and meta-analysis. Prev. Med. 45 (2007) 93-106
16. Frable W.J. Error reduction and risk management in cytopathology. Semin. Diagn. Pathol. 24 (2007) 77-88
17. Castle P.E. Is monitoring of human papillomavirus infection for viral persistence ready for use in cervical cancer screening?. Am. J. Epidemiol. 168 (2008) 138-144
18. Waller J., Marlow L.A., and Wardle J. The association between knowledge of HPV and feelings of stigma, shame, and anxiety. Sex Transm. Infect. 83 (2007) 155-159
19. Boronow R.C. Death of the Papanicolaou smear? A tale of three reasons. Am. J. Obstet. Gynecol. 179 (1998) 391-396
20. Gage J.C., Hanson V.W., Abbey K., Dippery S., Gardner S., Kubota J., et al. Number of cervical biopsies and sensitivity of colposcopy. Obstet. Gynecol. 108 (2006) 264-272
21. Kim J.J., Brisson M., Edmunds W.J., and Goldie S.J. Vaccine 26 Suppl 10 (2008 Aug 19) K76-K86
22. Vaccination coverage among adolescents aged 13-17 years - United States, 2007. Morb. Mort. Wkly Rep. 57 (2008) 1100-1103
23. Huh W.K., and and the Quadrivalent HPV Vaccine Phase IIB/III Investigators. Impact of quadrivalent human papillomavirus (HPV) L1 virus-like particle vaccine on the incidence of abnormal pap tests and cervical procedures. Gynecol. Oncol. 108 (2008) S10
24. Insinga R.P., Liaw K.L., Johnson L.G., and Madeleine M.M. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol. Biomarkers Prev. 17 (2008) 1611-1622
25. Klug S.J., Hukelmann M., Hollwitz B., Duzenli N., Schopp B., et al. Prevalence of human papillomavirus types in women screened by cytology in Germany. J. Med. Virology 79 (2007) 616-625
26. Kovacic M.B., Castle P.E., Herrero R., Schiffman M., Sherman M.E., et al. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res. 66 (2006) 10112-10119
27. Sargent A., Bailey A., Almonte M., Turner A., Thomson C., et al., for the ARTISTIC Study Group. Prevalence of type-specific infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br. J. Cancer 98 (2008) 1704-1709
28. Kjaer S.K., Breugelmans G., Munk C., Junge J., Watson M., et al. Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int. J. Cancer 123 (2008) 1864-1870
29. Wheeler C.M., Hunt W.C., Schiffman M., and Castle PE for the Atypical Squamous Cells of Undetermined Significance/Low-grade Squamous Intraepithelial Lesions Triage Study Group. Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J. Infect. Dis. 194 (2006) 1291-1299
30. Briolat J., Dalstein V., Saunier M., Joseph K., Caudroy S., et al. HPV prevalence, viral load, and physical state of HPV-16 in cervical smears of patients with different grades of CIN. Int. J. Cancer 121 (2007) 2198-2204
31. Wentzensen N., Schiffman M., Dunn S.T., Zuna R.E., Walker J., et al. Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma. Int. J. Cancer 124 (2009) 964-969
32. Gravitt P.E., van Doorn L.J., Quint W., Schiffman M., Hildesheim A., et al. Human papillomavirus (HPV) genotyping using paired exfoliated cervicovaginal cells and paraffin-embedded tissues to highlight difficulties in attributing HPV types to specific lesions. J. Clin. Microbiol. 45 (2007) 3245-3250
33. Sherman M.E., Wang S.S., Wheeler C.M., Rich L., Gravitt P.E., et al. Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions. Cancer Epidemiol. Biomarkers Prev. 12 (2003) 1038-1044
34. Schifman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer 111 (2007) 145-153
35. Kiviat N.B., Hawes S.E., and Feng Q. Screening for cervical cancer in the era of the HPV vaccine - the urgent need for both new screening guidelines and new biomarkers. JNCI 100 5 (2008) 308-320
36. Khan M.J., Castle P.E., Lorincz A.T., Wacholder S., Sherman M., Scott D.R., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst. 97 (2005) 1072-1079
37. Markowitz L.E., Dunne E.F., Saraiya M., Lawson H.W., Chesson H., and Unger ER the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. Quadrivalent human papillomavirus vaccine: recommendations of the advisory Committee on Immunization Practices. MMWR Recomm. Rep. 56 RR2 (2007) 1-24
38. Kim J.J., and Goldie S.J. Health and economic implications of HPV vaccination in the United States. N. Engl. J. Med. 359 (2008) 821-832
39. Tugetman J, Reimers LL, Ginsberg MS, Sandesara N, Kuo DY, Einstein MH. Sociodemographic and HPV risk factor assessment of early-adopting users of the HPV vaccine in the late catch-up population (ages 19-26) in an ethnically diverse, urban population. Presented at the 40th Annual SGO meeting San Antonio, TX 2009.
40. Cooper C.P., Saraiya M., McLean T.A., Hannan J., Liesmann J.M., et al. Pap test intervals used by physicians serving low-income women through the National Breast and Cervical Cancer Early Detection Program. J. Women's Health 14 (2005) 670-678
41. Ubel P.A., Jepson C., Baron J., Hershey J.C., and Asch D.A. The influence of cost-effectiveness information on physicians' cancer screening recommendations. Social Sci. Med. 56 (2003) 1727-1736
42. Sirovich B.E., Woloshin S., and Schwartz L.M. Screening for cervical cancer: will women accept less?. Am. J. Med. 118 (2005) 151-158